1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast 2016-2026: Opportunities for Leading Companies

Report Details
Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast 2016-2026: Opportunities for Leading Companies – our new study reveals trends, R&D progress, and predicted revenues
Our new report discusses issues and events affecting the Alzheimer’s disease therapeutics and diagnostics market. Our new report provides qualitative analyses to answer these key questions:
- How is the Alzheimer’s disease therapeutics and diagnostics market evolving?
- What is driving and restraining the Alzheimer’s disease therapeutics and diagnostics market growth?
- Which type of diagnostics will be the main drivers of the overall market from 2016 to 2026?
- How will political and regulatory factors influence the regional markets and submarkets?
- Who are the leading Alzheimer’s disease therapeutics and diagnostics companies, and what are their prospects over the forecast period?
- What are the predictions for M&A activity, consolidation for existing players and the potential prospects for new market entrants?

Forecasts from 2016-2026 and other analyses show you commercial prospects
Our new report provides quantitative analyses to answer these key questions:
- What are the market shares of the Alzheimer’s therapeutics disease market and Alzheimer’s diagnostics market in 2015?
- How will each of the drugs in the Alzheimer’s therapeutics market grow over the forecast period and how much revenue will these drugs account for in 2026?
- What Alzheimer’s disease drugs are in the development pipeline and what revenues will these drugs make when they come on the market?
- How will each of Alzheimer’s disease diagnostics market grow over the forecast period and how much revenue will these submarkets account for in 2026?
- How will the market shares of the national markets change by 2026 and which geographical region will lead the market in 2026?

Besides revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares. We provide original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT and Porter’s Five Forces Analysis), company profiles and commercial developments. Read the full transcripts of three exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales, including:
- Mr. Timothy Earle, Chief Operating Officer / Chief Business Officer, TauRx Pharmaceuticals Ltd
- Kevin Hrusovsky, Executive Chairman and CEO, Quanterix
- The Alzheimer’s Association Northern California and Northern Nevada

Many opportunities exist for diagnosis and treatment of Alzheimer’s. Our new study shows you the most promising and lucrative parts of that CNS market, helping you stay ahead

Discover sales predictions for the world market and submarkets
Along with revenue prediction of the overall world market, you see forecasts to 2026 for these two submarkets:
- Medicines for Alzheimer’s disease
- Diagnostics for Alzheimer’s (including biomarkers).

Our investigation discusses what stimulates and restrains business. You find dynamics of the industry and assess its potential sales, seeing agents likely to achieve the most success.

See revenue forecasts for Alzheimer’s disease drugs
How will leading drugs perform to 2026 at world level? Our study predicts individual revenues of three products:
- Namenda
- Aricept
- Exelon

And also three pipeline products:
- Solanezumab
- Gantenerumab
- MK-8931

What are the prospects in the leading regions and countries?
Developments worldwide expand the market for diagnosing, treating and monitoring neurodegenerative disorders. Developed and developing national markets hold high potential from 2015. The US remains the largest national market by value, accounting for 40% of global revenues.
In addition to analyses of the overall world market, you discover revenue forecasts for 12 leading national markets to 2026:
- US
- Japan
- Germany
- France
- UK
- Spain
- Italy
- China
- Brazil
- Russia
- India
- Rest of the World

Leading companies and potential for market growth
In 2015, the overall world market for Alzheimer’s disease therapeutics and diagnostics was worth $7.0bn, having experienced a plateau in revenue over recent years. Within this forecast period, revenue growth will increase in the second half of the forecast period due to the expected launch of new drugs. There are around 9 drugs in phase III of clinical development.

Our work shows you what organisation hold greatest potential. See profiles of leading companies in this sector:
- Pfizer
- Eisai
- Actavis
- Lundbeck
- Daiichi Sankyo
- Novartis
- TauRx
- vTv Therapeutics

In general, a company profile gives you the following information:
- Revenue forecasts for Alzheimer’s disease drugs from 2015 to 2026
- Discussion of a company’s activities and outlook
- Recent financial results
- Assessment of recent developments – mergers and acquisitions (M&A), new products, collaborations, including alliances, partnerships and joint ventures.

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

What affects producers of those diagnostic tests and medicines?
Our report discusses issues and events affecting that industry and market from 2015, including these:
- Research and development (R&D) – drugs, diagnostic tests, and related technologies
- Disease prevalence – expanding patient populations
- Disease-modifying drugs and obstacles to cures
- Regulatory guidelines – changes and opportunities.

The study also discusses other aspects of diagnosing and treating Alzheimer’s:
- Needs for Alzheimer’s treatments
- Drugs and related technologies to transform the market
- Biomarkers and diagnostic imaging technologies, including structural, functional, and molecular imaging
- Diagnostic tests in development
- Deep brain stimulation (functional neuromodulation)
- Intellectual property (IP), licensing agreements and partnerships.

Our 200-page report provides 132 charts. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and national level. You will see financial results, interviews trends and opportunities, and revenue predictions.

Benefit your work now through our updated study, gaining original industry and market analysis:
- Revenues for Alzheimer’s disease therapeutics and diagnostics market to 2026 at world level, also for Alzheimer’s drug submarket and Diagnostics submarket (Diagnostics Biomarkers and Others) and 3 medicines – assess outlooks for development, production, marketing and sales
- Forecasts to 2026 for 12 national markets in the Americas, Europe and Asia – investigate developed and developing countries for potential revenues
- Prospects for established competitors, rising companies and new entrants – explore portfolios, technologies, results, strategies, R&D and outlooks for success
- Analysis and forecast for Alzheimer’s pipeline drugs and diagnostics – uncover pipeline drugs, diagnostics, their forecast and recent development status
- Discussions of research and development – see progress in that industry, finding technological, clinical and commercial outlooks and opportunities
- Opinions from companies and other organisations – discover, through three interviews, views to help you stay ahead in knowledge
- Analysis of what stimulates and restrains that Alzheimer’s disease therapeutics and diagnostics market – assess challenges and strengths, helping you compete and gain advantages.

Table Of Contents

Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast 2016-2026: Opportunities for Leading Companies
1. Report Overview
1.1 The Alzheimer's Disease Therapeutics and Diagnostics Market Overview
1.2 The Alzheimer's Disease Therapeutics and Diagnostics Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain

2. Alzheimer's Disease: An Introduction
2.1 Neurodegenerative Diseases
2.1.1 What is Alzheimer's Disease?
2.1.2 What Causes Alzheimer's Disease?
2.1.2.1 Alzheimer's Disease: Type 3 Diabetes?
2.1.3 Management of Alzheimer's Disease
2.1.4 The Socio-Economic Impact of Alzheimer's Disease
2.1.5 Diagnosis of Alzheimer's Disease

3. Alzheimer's Disease Therapeutics and Diagnostics Market 2016-2026
3.1 Alzheimer's Disease Therapeutics and Diagnostics Market, 2015
3.2 Alzheimer's Disease Therapeutics and Diagnostics Market Forecast, 2015-2026
3.2.1 The Market Has Been Left Exposed to Intensified Generic Competition
3.2.2 Healthcare Costs for Alzheimer's Disease Will Surpass All Other Medical Expenses
3.2.3 New Diagnostics and Drugs Regulatory Guidelines Will Lower the Barriers to Entry
3.3 Drivers and Restraints

4. The Alzheimer's Disease Drugs Market, 2016-2026
4.1 Current Approaches and Unmet Needs in the Treatment of Alzheimer's disease
4.2 The Alzheimer's Disease Drugs Market, 2015
4.3 Changing Market Shares of the Leading Alzheimer's Disease Drugs, 2016-2026
4.4 The Alzheimer's Disease Drugs Market Forecast 2016-2026
4.5 Namenda
4.5.1 Namenda Sales Forecast, 2016-2026
4.6 Aricept
4.6.1 Aricept Sales Forecast, 2016-2026
4.7 Exelon
4.7.1 Exelon Sales Forecast, 2016-2026
4.8 Alzheimer's Disease Drugs Pipeline, 2015
4.8.1 New Guidelines: FDA to Relax Rules for the Approval of Alzheimer's Drugs
4.8.2 Will Novel Drug Development Strategies Prove Successful?
4.8.3 Solanezumab (Eli Lilly)
4.8.3.1 Solanezumab Sales Forecast 2016-2026
4.8.4 Gantenerumab (Roche)
4.8.4.1 Gantenerumab Pipeline Forecast, 2015-2026
4.8.5 MK-8931 (Merck)
4.8.5.1 The MK-8931 Pipeline Forecast, 2015-2026
4.8.6 Lu AE58054 (Lundbeck)
4.8.7 TTP488 (TransTechPharma)
4.8.8 LMTX (TauRx)
4.8.9 EVP-6124 (Forum Pharmaceuticals)
4.8.10 Axona (Accera)
4.8.11 AD-4833 (Takeda Pharmaceuticals)
4.9 Deep Brain Stimulation (Functional Neuromodulation)
4.10 Recent Research on Alzheimer's Disease

5. Leading Companies in the Alzheimer's Disease Drugs Market, 2015
5.1 Pfizer, Inc
5.1.1 Sales and Recent Performance Analysis, 2015
5.1.2 Pfizer: Aricept
5.1.3 Pfizer: RandD Capabilities and Alzheimer's Disease Drug Candidates
5.2 Eisai
5.2.1 Sales and Recent Performance Analysis, 2015
5.2.2 Eisai: Aricept
5.2.3 Eisai: RandD Capabilities and Alzheimer's Disease Drug Candidates
5.2.4 Collaboration with Biogen
5.2.5 Partnership with GE Healthcare for Diagnostic Development
5.3 Forest Laboratories (Acquired by Actavis)
5.3.1 Acquisition by Actavis
5.3.2 Forest: Namenda
5.3.3 Namenda's Sales and Recent Performance Analysis, 2014
5.4 Lundbeck A/S
5.4.1 Sales and Recent Performance Analysis, 2014
5.4.2 Lundbeck: RandD Capabilities
5.4.3 Lundbeck's Alzheimer's Disease Drug Pipeline
5.4.4 Lundbeck: Ebixa
5.5 Daiichi Sankyo
5.5.1 Financial Sales and Recent Performance, 2015
5.5.2 Daiichi Sankyo: Memary
5.6 Novartis AG
5.6.1 Sales and Recent Performance Analysis
5.6.2 Novartis: Exelon
5.6.3 eHealth Programme Delivering Innovation
5.6.4 Novartis: Alzheimer's Disease Drug Pipeline
5.7 TauRx
5.7.1 Partnership with Bayer Schering Pharma AG
5.8 vTv Therapeutics
5.8.1 TTP Translational Technology
5.8.2 vTv Therapeutics: Alzheimer's Disease Pipeline Portfolio

6. The Alzheimer's Disease Diagnostics Market, 2015-2026
6.1 There is Still a Strong Market Need for Effective Diagnosis
6.2 The Alzheimer's Disease Diagnostics Market, 2015
6.3 Changing Market Shares of Leading Alzheimer's Diagnostic Markets, 2015-2026
6.4 The Alzheimer's Diagnostics Market, 2015-2026
6.5 New Criteria and Guidelines to Diagnose Alzheimer's Disease
6.6 Biomarkers for Alzheimer's Disease
6.6.1 Leading Companies Pursuing Novel Biomarker Development Strategies
6.7 Alzheimer's Disease: Advances in Diagnostic Imaging Technologies
6.7.1 Structural Imaging
6.7.2 Functional Imaging
6.7.3 Molecular Imaging Technologies
6.7.3.1 Pittsburgh Compound B (PIB) (GE Healthcare)
6.7.3.2 Florbetapir F18 (18F-AV-45) (Eli Lilly)
6.7.3.3 Flutemetamol (GE Healthcare)
6.7.3.4 Florbetaben (Piramal Imaging)
6.8 Other Alzheimer's Diagnostics in Development
6.8.1 CSF Proteins
6.8.2 Blood Based Biomarkers for Alzheimer's Disease
6.8.3 Genetic Risk Profiling
6.8.4 Eye Tests
6.8.5 Nanoparticles
6.9 Leading Companies in the Alzheimer's Disease Diagnostics Market, 2015
6.9.1 Eli Lilly
6.9.1.1 Recent Performance and Sales Analysis, 2015
6.9.1.2 Alzheimer's Disease Research Effort
6.9.1.3 Solanezumab
6.9.1.4 Amyvid (Florbetapir F18)
6.9.1.5 Amyvid Receives Marketing Authorization from the European Commission
6.9.1.6 LY-2886721: Terminated Drug
6.9.1.7 LY3002813: Phase I
6.9.1.8 Eli Lilly Acquires Novel Tau Tangle Diagnostic Programme
6.9.2 Amarantus BioScience Holdings, Inc.
6.9.2.1 Recent Performance and Sales Analysis, 2014
6.9.2.2 LymPro
6.9.2.3 Intellectual Property Acquisitions
6.9.3 Piramal Enterprises
6.9.3.1 Piramal Imaging SA
6.9.3.2 U.S. and EMA Approval of Florbetaben
6.9.3.3 Manufacturing and Distribution Agreements
6.9.4 GE Healthcare
6.9.4.1 GE's Commitment to Imaging Research in the Alzheimer's Field
6.9.4.2 Regulatory Approval of Flutemetamol
6.9.4.3 Licensing Agreements for Flutemetamol
6.9.5 Navidea
6.9.5.1 NAV4694 (Fluorine-18)
6.9.5.2 Collaboration Agreements
6.9.5.3 NAV4694 Clinical Development
6.9.6 DiaGenic

7. The Leading National Markets, 2015-2026
7.1 Regional Breakdown of the Global Alzheimer's Disease Therapeutics and Diagnostic Market, 2015
7.1.1 The US, Japan and Europe Represent More than 80% of the Total Market
7.2 The Global Alzheimer's Disease Therapeutics and Diagnostics Market: Regional Forecast, 2015-2026
7.3 Changing Market Shares of Leading National Markets 2015-2026
7.4 The US Alzheimer's Disease Therapeutics and Diagnostics Market, 2015-2026
7.4.1 One in Nine Over the Age of 65 has AD in the US
7.4.2 The US Will Remain the Largest Market Over the Forecast Period
7.5 The European Alzheimer's Disease Therapeutics and Diagnostics Market, 2015-2026
7.5.1 The German Alzheimer's Disease Therapeutics and Diagnostics Market Forecast, 2015-2026
7.5.2 The French Alzheimer's Disease Therapeutics and Diagnostics Market Forecast, 2015-2026
7.5.3 The UK Alzheimer's Disease Therapeutics and Diagnostics Market Forecast, 2015-2026
7.5.4 The Spanish Alzheimer's Disease Therapeutics and Diagnostics Market Forecast, 2015-2026
7.5.5 The Italian Alzheimer's Disease Therapeutics and Diagnostics Market Forecast, 2015-2026
7.5.6 The Rest of Europe Alzheimer's Disease Therapeutics and Diagnostics Market Forecast, 2015-2026
7.6 The Japanese Alzheimer's Disease Therapeutics and Diagnostics Market Forecast, 2015-2026
7.7 The Chinese Alzheimer's Disease Therapeutics and Diagnostics Market Forecast, 2015-2026
7.8 The Indian Alzheimer's Disease Therapeutics and Diagnostics Market Forecast, 2015-2026
7.9 The Brazilian Alzheimer's Disease Therapeutics and Diagnostics Market Forecast, 2015-2026
7.10 The Russian Alzheimer's Disease Therapeutics and Diagnostics Market Forecast, 2015-2026
7.11 The Rest of the World Alzheimer's Disease Therapeutics and Diagnostics Market Forecast, 2015-2026

8. Qualitative Analysis of the Alzheimer's Disease: Therapeutics and Diagnostics Market, 2016-2026
8.1 SWOT Analysis
8.2 Strengths
8.2.1 Alzheimer's Disease is a High Profile Disease
8.2.2 Expanding Patient Population
8.2.3 Strong RandD Pipeline in Both Sectors of the Market
8.3 Weaknesses
8.3.1 Current Drugs Only Treat the Symptoms of Alzheimer's Disease
8.3.2 Recent Failures of Promising Drug Candidates in Clinical Trials
8.3.3 Poor Macroeconomic Conditions in Key Regions of the Market
8.4. Opportunities
8.4.1 Regulations Seeking Improved Standards of Alzheimer's Disease Drug Development
8.4.2 Neurodegenerative Diseases Have Strong RandD
8.4.3 Emerging Markets Will Help Drive the Market
8.4.4 Advances in Diagnostic Technologies Will Improve Drug Market Penetration
8.5 Threats
8.5.1 Patent Expiries Will Lead to Further Generic Competition
8.5.2 New AD Therapies Face Political, Commercial and Social Pressures
8.6 Porter's Five Force Analysis
8.6.1 Rivalry Among Competitors
8.6.2 Threats of New Entrants
8.6.3 Powers of Suppliers
8.6.4 Bargaining Power of Buyers
8.6.5 Threat of Substitutes

9. Research Interviews from Our Survey
9.1 Mr. Timothy Earle, Chief Operating Officer / Chief Business Officer, TauRx Pharmaceuticals Ltd
9.1.1 Alzheimer's Treatment in Late Stage Development
9.1.2 Alzheimer's Severe Under diagnosis
9.1.3 The Benefits of Alzheimer's Diagnosis: A Future Prospect
9.1.4 Alzheimer's Treatment: The Greatest Challenge
9.2 Kevin Hrusovsky, Executive Chairman and CEO, Quanterix
9.2.1 Ultra Sensitive Automated Immunoassay Platform for Alzheimer's
9.2.2 Alzheimer's Disease Diagnosis Biomarkers
9.2.3 Quanterix: Future Developments
9.3 The Alzheimer's Association Northern California and Northern Nevada
9.3.1 Alzheimer's Treatment in Late Stage Development
9.3.2 Novel Biomarkers: Critical for Alzheimer's Diagnosis
9.3.3 A Push to Improve the Success of Alzheimer's Research

10. Conclusion
10.1 Novel Diagnostic Technologies Will Emerge First and Then the Disease Modifying Drugs
10.2 Disease Modifying Drugs Will Transform the Declining Alzheimer's Market
10.3 Demographics Will Help Drive the Market Over the Forecast Period
10.4 Medicines and Diagnostic Tests for Alzheimer's Disease Hold Great Potential from 2015 to 2026
10.5 Research for Alzheimer's Happening all Over the World

List of Tables
Table 1.1 The Alzheimer's Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2026
Table 2.1 Leading Sectors in the Neurodegenerative Disease Market, 2015
Table 2.2 Imaging Technologies Used in Alzheimer's Research, 2015
Table 3.1 The Global Alzheimer's Disease Therapeutics and Diagnostics Market: Revenues ($bn) and Market Shares (%) by Sector, 2015
Table 3.2 Alzheimer's Disease Therapeutics and Diagnostics Market Forecasts: Revenues ($bn), AGR (%), CAGR (%), 2016-2026
Table 3.3 The Alzheimer's Disease Therapeutics and Diagnostics Market: Drivers and Restraints, 2015
Table 4.1 The Alzheimer's Disease Drugs Market: Revenues ($bn) and Market Shares (%) by Leading Drugs, 2015
Table 4.2 Market Shares (%) of the Leading Alzheimer's Drugs, 2015, 2020, 2026
Table 4.3 The Alzheimer's Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2026
Table 4.4 Namenda: Sales Forecast ($bn), AGR (%), CAGR (%), 2015-2026
Table 4.5 Aricept: Sales Forecast ($bn), AGR (%), CAGR (%), 2015-2026
Table 4.6 Exelon: Sales Forecast ($bn), AGR (%), CAGR (%), 2015-2026
Table 4.7 Selected List of Alzheimer's Disease Drugs in the Pipeline, 2016
Table 4.8 Continued Selected List of Alzheimer's Disease Drugs in the Pipeline, 2016
Table 4.9 Eli Lilly: Solanezumab Sales Forecast ($bn), AGR (%), CAGR (%), 2015-2026
Table 4.10 Roche: Gantenerumab Sales Forecast ($bn), AGR (%), CAGR (%), 2015-2026
Table 4.11 Merck: MK-8931 Sales Forecast ($bn), AGR (%), CAGR (%), 2015-2026
Table 5.1 Pfizer: Revenues ($bn) and Revenue Shares (%) by Sector, 2015
Table 5.2 Pfizer: Aricept Sales Forecast ($bn), AGR (%), CAGR (%), 2015-2026
Table 5.3 Pfizer: Alzheimer's Disease Drug Pipeline, 2015
Table 5.4 Eisai: Aricept Regional Sales ($m), AGR (%), 2013
Table 5.5 Eisai: Aricept Sales Forecast ($bn), AGR (%), CAGR (%), 2015-2026
Table 5.6 Biogen: Alzheimer's Disease Drugs Pipeline, 2015
Table 5.7 Forest: Namenda's Historical Revenues ($bn) and AGR (%), 2010-2014
Table 5.8 Forest: Namenda Sales Forecast ($bn), AGR (%), CAGR (%), 2015-2026
Table 5.9 Lundbeck: Revenue ($bn) and Revenue Share (%) by Region, 2014
Table 5.10 Ebixa: Revenue ($bn) and Revenue Share (%) by Region, 2014
Table 5.11 Ebixa: Sales Forecast ($bn), AGR (%), CAGR (%), 2015-2026
Table 5.12 Daiichi Sankyo: Memary Sales Forecast ($bn), AGR (%), CAGR (%), 2015-2026
Table 5.13 Novartis: Revenue ($bn) and Revenue Shares (%) by Segment, 2015
Table 5.14 vTv Therapeutics : Alzheimer's Disease Drugs Pipeline, 2015
Table 6.1 The Alzheimer's Disease Diagnostics Market: Revenues ($bn) and Market Shares (%) by Segment, 2015
Table 6.2 Market Shares (%) of the Leading Alzheimer's Diagnostics Markets, 2015, 2020 and 2026
Table 6.3 The Alzheimer's Disease Diagnostics Market Forecast: Revenues ($bn), AGR (%), CAGR (%) by Segment, 2015-2026
Table 6.4 Key Alzheimer's Diagnostic Tests in Development, 2015
Table 6.5 (Continued) Key Alzheimer's Diagnostic Tests in Development, 2015
Table 6.6 DiaGenic: Alzheimer's Disease Diagnostics Pipeline and Current Developments, 2015
Table 7.1 The Alzheimer's Disease Therapeutics and Diagnostics Market: Revenues ($bn) and Market Share (%) by Region, 2015
Table 7.2 The Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR (%) by Region, 2015-2026
Table 7.3 Regional Alzheimer's Disease Therapeutics and Diagnostics Market Forecast CAGR (%), 2013-2018, 2018-2024, 2015-2026
Table 7.4 Market Shares (%) of the Leading Regional Alzheimer's Disease Therapeutics and Diagnostics Markets, 2015, 2020 and 2026
Table 7.5 The US Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR(%), 2015-2026
Table 7.6 The European Alzheimer's Therapeutics and Diagnostics Market: Revenue ($bn), European Market Share (%) and Global Market Share (%) by Leading Countries, 2015
Table 7.7 The European Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR(%), 2015-2026
Table 7.8 The German Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR(%), 2015-2026
Table 7.9 The French Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR(%), 2015-2026
Table 7.10 The UK Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR(%), 2015-2026
Table 7.11 The Spanish Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR(%), 2015-2026
Table 7.12 The Italian Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR(%), 2015-2026
Table 7.13 The Rest of Europe Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR(%), 2015-2026
Table 7.14 The Japanese Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR(%), 2015-2026
Table 7.15 The Chinese Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR(%), 2015-2026
Table 7.16 The Indian Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR(%), 2015-2026
Table 7.17 The Brazilian Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR(%), 2015-2026
Table 7.18 The Russian Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR(%), 2015-2026
Table 7.19 The Rest of the World Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR(%), 2015-2026
Table 8.1SWOT Analysis of the Alzheimer's Disease Therapeutics and Diagnostics Market, 2015
Table 10.1 The Global Alzheimer's Disease Therapeutics and Diagnostics Market: Revenues ($bn) in 2015, 2020 and 2026 and CAGR (%) 2015-2020 and 2020-2026 by Region
Table 10.2 The Global Alzheimer's Disease Therapeutics and Diagnostics Market ($bn) by Sector, 2015, 2020 and 2026

List of Figures
Figure 1.1 Alzheimer's Disease Therapeutics and Diagnostics: Overview of Submarkets and Segments
Figure 3.1 The Global Alzheimer's Disease Therapeutics and Diagnostics Market: Revenue ($bn) by Sector, 2015
Figure 3.2 The Global Alzheimer's Disease Therapeutics and Diagnostics Market: Market Share (%) by Sector, 2015
Figure 3.3 The Global Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), 2015-2026
Figure 4.1 The Alzheimer's Disease Drugs Market: Revenues ($bn) by Leading Drugs, 2015
Figure 4.2 The Alzheimer's Disease Drugs Market: Market Shares (%) by Leading Drugs, 2015
Figure 4.3 The Alzheimer's Therapeutics Market: Market Shares (%) by Drug, 2020
Figure 4.4 The Alzheimer's Therapeutics Market: Market Shares (%) by Drug, 2026
Figure 4.5 The Alzheimer's Disease Drugs Market Forecast: Revenue ($bn), 2015-2026
Figure 4.6 Namenda: Sales Forecast ($bn), 2015-2026
Figure 4.7 Aricept: Sales Forecast ($bn), 2015-2026
Figure 4.8 Exelon: Sales Forecast ($bn), 2015-2026
Figure 4.9 Eli Lilly: Solanezumab Sales Forecast ($bn), 2015-2026
Figure 4.10 Roche: Gantenerumab Sales Forecast ($bn), 2015-2026
Figure 4.11 Merck: MK-8931 Sales Forecast ($bn), 2015-2026
Figure 5.1 Pfizer: Historical Revenues ($bn), 2012-2015
Figure 5.2 Pfizer: Revenues ($bn) by Sector, 2015
Figure 5.3 Pfizer: Revenue Shares (%) by Sector, 2015
Figure 5.4 Pfizer: Aricept Sales Forecast ($bn), 2015-2026
Figure 5.5 Pfizer: Historical RandD Expenditure ($bn), 2013-2015
Figure 5.6 Eisai: Aricept Sales Forecast ($bn), 2015-2026
Figure 5.7 Eisai: Historical RandD Expenditure ($bn), 2013-2014
Figure 5.8 Forest: Namenda's Historical Revenue ($bn), 2010-2014
Figure 5.9 Forest: Namenda Sales Forecast ($bn), 2015-2026
Figure 5.10 Lundbeck: Revenue Share (%) by Region, 2014
Figure 5.11 Lundbeck: Revenue Share ($bn) by Region, 2014
Figure 5.12 Lundbeck: RandD Expenditure ($bn), 2013-2014
Figure 5.13 Ebixa: Revenue ($bn) by Region, 2014
Figure 5.14 Ebixa: Revenue Shares (%) by Region, 2014
Figure 5.15 Ebixa: Sales Forecast ($bn), 2015-2026
Figure 5.16 Daiichi Sankyo: Historical Revenue ($bn), 2012-2014
Figure 5.17 Daiichi Sankyo: Memary Historical Revenue ($bn), 2013-2014
Figure 5.18 Daiichi Sankyo: Memary Sales Forecast ($bn), 2015-2026
Figure 5.19 Novartis: Historical Revenues ($bn), 2012-2015
Figure 5.20 Novartis: Revenues ($bn) by Segment, 2015
Figure 5.21 Novartis: Revenue Shares(%) by Segment, 2015
Figure 5.22 Exelon: Revenue Shares (%) by Region, 2013
Figure 6.1 The Alzheimer's Disease Diagnostics Market: Revenues ($bn) by Segment, 2015
Figure 6.2 The Alzheimer's Disease Diagnostics Market: Market Shares (%) by Segment, 2015
Figure 6.3 The Alzheimer's Diagnostics Market: Market Share (%) by Segment, 2020
Figure 6.4 The Alzheimer's Diagnostics Market: Market Share (%) by Segment, 2026
Figure 6.5 The Alzheimer's Disease Diagnostics Market Forecast: Revenues ($bn), 2015-2026
Figure 6.6 Eli Lilly: Historical Revenue ($bn), 2012-2015
Figure 6.7 AmarantusBioScience: RandD Costs ($m), 2013-2014
Figure 7.1 The Alzheimer's Disease Therapeutics and Diagnostics Market: Revenues ($bn) by Region, 2015
Figure 7.2 The Alzheimer's Disease Therapeutics and Diagnostics Market: Market Shares (%) by Region, 2015
Figure 7.3 Regional Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: CAGR (%), 2015-2020
Figure 7.4 Regional Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: CAGR (%), 2020-2026
Figure 7.5 Regional Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: CAGR (%), 2015-2026
Figure 7.6 The Alzheimer's Therapeutics and Diagnostics Market: Market Shares (%) by Region, 2020
Figure 7.7 The Alzheimer's Therapeutics and Diagnostics Market: Market Shares (%) by Region, 2026
Figure 7.8 The US Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), 2015-2026
Figure 7.9 The US Demographics: No. of People Aged 65 or Over, 2015 and 2026 Forecast
Figure 7.10 The European Alzheimer's Disease Therapeutics and Diagnostics Market: Revenue ($bn) by Leading Countries, 2015
Figure 7.11 The European Alzheimer's Disease Therapeutics and Diagnostics Market : Market Shares (%) by Leading Countries, 2015
Figure 7.12 The European Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), 2015-2026
Figure 7.13 The German Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), 2015-2026
Figure 7.14 The French Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), 2015-2026
Figure 7.15 The UK Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), 2015-2026
Figure 7.16 The Spanish Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), 2015-2026
Figure 7.17 The Italian Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), 2015-2026
Figure 7.18 The Other European Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn),2015-2026
Figure 7.19 The Japanese Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), 2015-2026
Figure 7.20 The Chinese Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), 2015-2026
Figure 7.21 China's Historical Healthcare Expenditure ($bn), 2001-2010
Figure 7.22 The Indian Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), 2015-2026
Figure 7.23 The Brazilian Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($m), 2015-2026
Figure 7.24 The Russian Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), 2015-2026
Figure 7.25 The Rest of the World Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), 2015-2026
Figure 8.1 The Global Over 65 Population: Forecast (millions), 2010-2050
Figure 8.2 Porter's Five Force Analysis of the Alzheimer's Disease Therapeutics and Diagnostics Market, 2015
Figure 10.1 The Global Alzheimer's Disease Therapeutics and Diagnostics Market: Revenues ($bn) in 2015, 2020 and 2026
Figure 10.2 The Global Alzheimer's Disease Therapeutics and diagnostics Market ($bn) by Segment, 2015, 2020 and 2026

Companies Listed
AbbVie
AC Immune
Acadia Pharmaceuticals
Accera
Actavis
Adamas Pharmceuticals
Affiris
Amarantus BioSciences
Amorphis
Archer Pharmaceuticals
Astex
AstraZeneca
Avanir Pharmaceuticals
Avineuro Pharmaceuticals
Baxter
Bayer
Bayer Schering Pharma
Biogen
bioMerieux
Ceregene
Chiesi Farmaceutici
Cognoptix
Cytos
Daiichi Sankyo
DiaGenic
Eisai
Elan
Eli Lilly
EnVivo Pharmaceuticals
Forest Laboratories
Forum Pharmaceuticals
Foundation Medical Partners
Functional Neuromodulation
GE Healthcare
General Electric
Genervon Biopharmaceuticals
Genesys Capital
GSK
Hisamitsu Pharmaceutical
Humanetics
IBA Molecular
JandJ
Janssen Alzheimer Immunotherapy Research and Development
Janssen Pharmaceutical K. K
Kareus Therapeutics
LabCorp
Luminex
Lundbeck
Medtronic
Merck and Co
Merz
Meso Scale Diagnostics
Metabolic Solutions Development Company
MorphoSys
Nanotherapeutics
Navidea
NextGen Sciences
Novartis
Novo Nordisk
Ono Pharmaceutical
OPKO
Ortho Clinical Diagnostics
Otsuka Pharmaceutical
Oxford BioDynamics
Par Pharmaceuticals
Pfizer
Piramal Enterprises
Piramal Imaging
Proteome Sciences
ProteoTech
Proterra
QR Pharma
Quanterix
Raptor Pharmaceutical
Resverlogix
Roche
Roche Diagnostics
Saladax
Sangamo BioSciences
Sanofi
sGC Pharma
Shionogi
Shire
Siemens Medical Solutions USA
Somalogic
Sonexa Therapeutics
Sun Pharma
T3D Therapeutics
Takeda
Targacept
TauRx
Toyama Chemical
Transition Therapeutics
TransTech Pharma
United Biomedical
VIVUS
Wyeth

Organisations mentioned in the report
Alzheimer's Association International Conference (AAIC)
Alzheimer's Research UK
Assogenerici (Italy)
Cambridge University
Cleveland Clinic Lou Ruvo Center for Brain Health
Dementia UK
French Economic Committee
King's College London
Ministry of Health, Labout and Welfare (MHLW) (Japan)
National Health Services (Italy)
National Health Services (NHS) (UK)
National Institute of Clinical Excellence (NICE)
National Institute of Health (NIH)
The Alzheimer's Association
The Centers for Medicare and Medicaid Services (CMS)
The Central Drug Standard Control Organisation (CDSCO)
The Duke University
The European Commission
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP)
The Food and Drug Administration FDA (US)
The Health and Social Care Information Centre
The National Institute of Aging (NIA)
The Supreme Court of Japan
The University of Aberdeen
The University of Cologne
The University of Pittsburgh
Trinity College Dublin
United Nations (UN)
World Health Organisation (WHO)

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Alzheimer’s disease (AD) - Market Insights, Epidemiology and Market Forecast-2023

Alzheimer’s disease (AD) - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

DelveInsight’s Alzheimer’s disease (AD) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Alzheimer’s disease ...

Amyotrophic lateral sclerosis (ALS)- Market Insights, Epidemiology and Market Forecast-2023

Amyotrophic lateral sclerosis (ALS)- Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Amyotrophic lateral sclerosis (ALS) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of ...

Global Multi Infarct Dementia Market Insights, Opportunity Analysis, Market Shares and Forecast, 2016 - 2022

Global Multi Infarct Dementia Market Insights, Opportunity Analysis, Market Shares and Forecast, 2016 - 2022

  • $ 3900
  • Industry report
  • November 2016
  • by Occams

"Global Multi Infarct Dementia Market Research Report 2016" by OBRC, is an extensive study on present state of the Multi Infarct Dementia Market. The global multi-infarct dementia is estimated to reach ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.